The global Tofacitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Tofacitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Tofacitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Tofacitinib include Pfizer, Globe Pharmaceuticals, Delta Pharma Limited, Beacon Pharmaceuticals and Drug International, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Tofacitinib, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tofacitinib.
Report Scope
The Tofacitinib market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tofacitinib market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tofacitinib manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Pfizer
Globe Pharmaceuticals
Delta Pharma Limited
Beacon Pharmaceuticals
Drug International
Segment by Type
5mg*60 Tablets
5mg*10 Tablets
10mg*10 Tablets
5mg*30 Tablets
5mg*14 Tablets
10mg*14 Tablets
Segment by Application
Rheumatoid Arthritis
Ulcerative Colitis
Psoriasis
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Tofacitinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Tofacitinib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Tofacitinib 麻豆原创 Overview
1.1 Product Overview and Scope of Tofacitinib
1.2 Tofacitinib Segment by Type
1.2.1 Global Tofacitinib 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 5mg*60 Tablets
1.2.3 5mg*10 Tablets
1.2.4 10mg*10 Tablets
1.2.5 5mg*30 Tablets
1.2.6 5mg*14 Tablets
1.2.7 10mg*14 Tablets
1.3 Tofacitinib Segment by Application
1.3.1 Global Tofacitinib 麻豆原创 Value by Application: (2024-2030)
1.3.2 Rheumatoid Arthritis
1.3.3 Ulcerative Colitis
1.3.4 Psoriasis
1.3.5 Others
1.4 Global Tofacitinib 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Tofacitinib Revenue 2019-2030
1.4.2 Global Tofacitinib Sales 2019-2030
1.4.3 Global Tofacitinib 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Tofacitinib 麻豆原创 Competition by Manufacturers
2.1 Global Tofacitinib Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Tofacitinib Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Tofacitinib Average Price by Manufacturers (2019-2024)
2.4 Global Tofacitinib Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Tofacitinib, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Tofacitinib, Product Type & Application
2.7 Tofacitinib 麻豆原创 Competitive Situation and Trends
2.7.1 Tofacitinib 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Tofacitinib Players 麻豆原创 Share by Revenue
2.7.3 Global Tofacitinib 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Tofacitinib Retrospective 麻豆原创 Scenario by Region
3.1 Global Tofacitinib 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Tofacitinib Global Tofacitinib Sales by Region: 2019-2030
3.2.1 Global Tofacitinib Sales by Region: 2019-2024
3.2.2 Global Tofacitinib Sales by Region: 2025-2030
3.3 Global Tofacitinib Global Tofacitinib Revenue by Region: 2019-2030
3.3.1 Global Tofacitinib Revenue by Region: 2019-2024
3.3.2 Global Tofacitinib Revenue by Region: 2025-2030
3.4 North America Tofacitinib 麻豆原创 Facts & Figures by Country
3.4.1 North America Tofacitinib 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Tofacitinib Sales by Country (2019-2030)
3.4.3 North America Tofacitinib Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Tofacitinib 麻豆原创 Facts & Figures by Country
3.5.1 Europe Tofacitinib 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Tofacitinib Sales by Country (2019-2030)
3.5.3 Europe Tofacitinib Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Tofacitinib 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Tofacitinib 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Tofacitinib Sales by Country (2019-2030)
3.6.3 Asia Pacific Tofacitinib Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Tofacitinib 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Tofacitinib 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Tofacitinib Sales by Country (2019-2030)
3.7.3 Latin America Tofacitinib Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Tofacitinib 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Tofacitinib 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Tofacitinib Sales by Country (2019-2030)
3.8.3 Middle East and Africa Tofacitinib Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Tofacitinib Sales by Type (2019-2030)
4.1.1 Global Tofacitinib Sales by Type (2019-2024)
4.1.2 Global Tofacitinib Sales by Type (2025-2030)
4.1.3 Global Tofacitinib Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Tofacitinib Revenue by Type (2019-2030)
4.2.1 Global Tofacitinib Revenue by Type (2019-2024)
4.2.2 Global Tofacitinib Revenue by Type (2025-2030)
4.2.3 Global Tofacitinib Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Tofacitinib Price by Type (2019-2030)
5 Segment by Application
5.1 Global Tofacitinib Sales by Application (2019-2030)
5.1.1 Global Tofacitinib Sales by Application (2019-2024)
5.1.2 Global Tofacitinib Sales by Application (2025-2030)
5.1.3 Global Tofacitinib Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Tofacitinib Revenue by Application (2019-2030)
5.2.1 Global Tofacitinib Revenue by Application (2019-2024)
5.2.2 Global Tofacitinib Revenue by Application (2025-2030)
5.2.3 Global Tofacitinib Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Tofacitinib Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Tofacitinib Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Tofacitinib Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Globe Pharmaceuticals
6.2.1 Globe Pharmaceuticals Corporation Information
6.2.2 Globe Pharmaceuticals Description and Business Overview
6.2.3 Globe Pharmaceuticals Tofacitinib Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Globe Pharmaceuticals Tofacitinib Product Portfolio
6.2.5 Globe Pharmaceuticals Recent Developments/Updates
6.3 Delta Pharma Limited
6.3.1 Delta Pharma Limited Corporation Information
6.3.2 Delta Pharma Limited Description and Business Overview
6.3.3 Delta Pharma Limited Tofacitinib Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Delta Pharma Limited Tofacitinib Product Portfolio
6.3.5 Delta Pharma Limited Recent Developments/Updates
6.4 Beacon Pharmaceuticals
6.4.1 Beacon Pharmaceuticals Corporation Information
6.4.2 Beacon Pharmaceuticals Description and Business Overview
6.4.3 Beacon Pharmaceuticals Tofacitinib Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Beacon Pharmaceuticals Tofacitinib Product Portfolio
6.4.5 Beacon Pharmaceuticals Recent Developments/Updates
6.5 Drug International
6.5.1 Drug International Corporation Information
6.5.2 Drug International Description and Business Overview
6.5.3 Drug International Tofacitinib Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Drug International Tofacitinib Product Portfolio
6.5.5 Drug International Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Tofacitinib Industry Chain Analysis
7.2 Tofacitinib Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Tofacitinib Production Mode & Process
7.4 Tofacitinib Sales and 麻豆原创ing
7.4.1 Tofacitinib Sales Channels
7.4.2 Tofacitinib Distributors
7.5 Tofacitinib Customers
8 Tofacitinib 麻豆原创 Dynamics
8.1 Tofacitinib Industry Trends
8.2 Tofacitinib 麻豆原创 Drivers
8.3 Tofacitinib 麻豆原创 Challenges
8.4 Tofacitinib 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Pfizer
Globe Pharmaceuticals
Delta Pharma Limited
Beacon Pharmaceuticals
Drug International
听
听
*If Applicable.